StockData

BridgeBio Pharma vs Travere Therapeutics

BBIO and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BBIO and TVTX compare

BridgeBio Pharma is the larger company, worth 3.2 times as much as Travere Therapeutics ($15.1B against $4.7B).

BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 77.1% for Travere Therapeutics).

Travere Therapeutics scores higher on the StockData Score (6 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBBIOTVTX
Size and price
Market cap$15.1B$4.7B
Share price$77.36$49.70
Change, 1 year18.9%46.7%
Change, 5 years95.6%71.2%
Beta (5Y)0.221.95
Employees834497
StockData Score
Total score36 (better)
Valuation score00
Growth score23 (better)
Performance score02 (better)
Health score11
Dividend score00
Valuation
P/S15.9×7.9× (better)
P/B–191×
EV/EBITDA–192×
FCF yield−2.5%–
Fair value–$6.04
Margin of safety–−723%
Growth
Revenue growth (TTM)167% (better)77.1%
Revenue growth, 5Y average127% (better)19.9%
Profitability
Gross margin94.3%98.6% (better)
Operating margin−38.5%−6.8% (better)
Net margin–−7.4%
FCF margin−39.1%–
Return on equity–−152%
Financial health
Interest coverage−7.1×−4.3× (better)
Current ratio2.094.05 (better)
Altman Z-score0.132.19 (better)
Piotroski F-score–7
Dividends and buybacks
Buyback yield1.7%–
Shareholder yield1.7% (better)0.00%
Ownership
Held by institutions99.4%112%
Held by insiders35.6%1.6%
Insider net buying, 12 months−$84.8M (better)−$110M
Superinvestors holding1–
Short interest, % of float16.6%10.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.